Business Context and Reporting Period
This Form 8-K was filed by Recursion Pharmaceuticals, Inc. on February 7, 2024, reporting events that occurred on February 6, 2024. The filing addresses executive leadership changes within the company's business development and corporate initiatives functions.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation and severance arrangements.
Material Changes
The primary material change reported is the restructuring of executive roles:
- Dr. Shafique Virani: Transitioned from Chief Business Officer to Senior Strategic Advisor.
- Matthew Kinn: Promoted to the executive team as Senior Vice President, Business Development and Corporate Initiatives, assuming all responsibilities previously held by Dr. Virani.
Compensation, Risks, and Unusual Items
Dr. Virani entered into transition and advisory agreements with the following terms:
- Advisory Fees: $1,000 per hour, with a minimum of $25,000 per month (February–July) and $15,000 per month (August–December).
- Equity: Continued vesting of existing equity awards during the advisory period.
- Benefits: Company payment of COBRA health premiums for Dr. Virani and eligible dependents.
- Release Payment: A one-time cash payment of $2,500 upon execution of a supplemental release of claims.
- Termination Provision: If the agreement is terminated prior to August 1, 2024, Dr. Virani is entitled to a lump sum starting at $390,000 (if terminated in February), decreasing by $65,000 for each subsequent month.
The filing notes that the full text of the agreements will be filed as exhibits to a future periodic report.
Investor Verification Checklist
- Verify the exact terms of the transition and advisory agreements once filed as exhibits to the next periodic report.
- Monitor the impact of the leadership transition on ongoing corporate development transactions and partnerships.
- Confirm the total potential liability for the termination provision if the advisory agreement is ended early.